Business Daily Media

Men's Weekly

.

Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment

  • Berlin Cures, a clinical-stage biotechnology firm, advances innovative treatment aimed at combating Long COVID, currently impacting over 100 million people globally.
  • Over 50% of patients in randomized placebo-controlled Phase-II-trial now recruited; no issues regarding safety observed.
  • Berlin Cures innovative platform develops novel aptamer-based drugs to neutralize pathogenic functional autoantibodies, targeting diseases.

  • BERLIN, GERMANY - Media OutReach Newswire - 4 March 2024 - Berlin Cures, a clinical-stage biotechnology company, has reached a significant milestone in its Europe-wide clinical trial for Long COVID, effectively enrolling over 50% of the targeted 114 patients and expanding the study's inclusion criteria. The trial is investigating the efficacy of BC 007, the company's pioneering drug candidate designed to neutralize functional autoantibodies (fAABs), which play a key role in the persistence of Long COVID symptoms.

    BC 007
    BC 007

    The study is actively progressing across 12 trial centers in Finland, Germany, Austria, Switzerland, and Spain, exemplifying the collaborative effort to address Long COVID, which has developed into a significant global health issue. Progress is strong and another seven centers are set to join soon. Anticipated results in autumn 2024 will pave the way for the next development stage, with Berlin Cures currently seeking additional funding to complete Phase II and initiate the crucial Phase III study necessary for regulatory approval.

    "Long COVID has impacted the lives of over 100 million people globally, altering the day-to-day existence of countless individuals," states Oliver von Stein, CEO of Berlin Cures. "Our mission with BC 007 is not just to treat a virus's lingering effects but to restore the quality of life for those affected. By harnessing the power of innovative science, we are on the cusp of a breakthrough that could return health and vitality to millions. The progress of our clinical trial across Europe is a beacon of hope and a testament to what we can achieve through collaboration and dedication."

    Dr Oliver von Stein
    Dr Oliver von Stein

    As a biotech company focused on neutralizing fAABs, Berlin Cures stands at the forefront of developing innovative treatments for a variety of autoimmune diseases, including Long COVID, heart failure, glaucoma, and many others. Its drug candidate, BC 007, represents a promising solution by targeting harmful fAABs implicated in a range of autoimmune conditions such as Long COVID.

    The ongoing Phase II clinical trial in Long COVID seeks to deliver conclusive and reliable results on the drug's effectiveness and safety for patients. The company anticipates a positive outcome, which will pave the way to proceed with a larger Phase III study, crucial for BC 007's approval.

    BC 007 Could Potentially Cure Long COVID for Many
    Current estimates indicate that functional autoantibodies (fAABs) are detectable in blood tests in about 40% of all Long COVID patients. Functional autoantibodies are a specific type of autoantibody that can develop as an immune response following infections, mistakenly target the body's tissues or cells. This interaction can lead to autoimmune diseases. Unlike normal antibodies that protect against infections, fAABs disrupt normal functions by binding to cell receptors or other proteins, often imitating or blocking natural signals needed for healthy cell functions. This disruption can result in a variety of autoimmune diseases, depending on the target of the autoantibodies and the role of the targeted tissue in the body.

    "The presence of fAABs in such a large portion of patients highlights the potential of BC 007 to combat the underlying cause of Long COVID symptoms in a significant group of affected individuals. We are convinced of BC 007's therapeutic potential and are actively seeking support to prepare for a larger Phase III study," adds Oliver von Stein. "Our commitment to finding a cure for diseases caused by fAABs remains steadfast, supported by private funding since our inception."

    Versatile Platform Technology Targeting Multiple Medical Conditions
    The potential of BC 007 extends beyond treating a single disease, making it a so-called platform technology. By neutralizing fAABs, BC 007 could potentially act against many fAAB-associated diseases.

    Built on more than two decades of fAAB-research, Berlin Cures has advanced BC 007 into clinical trials. This journey has demonstrated efficacy in Phase I studies with fAAB-positive volunteers and in a Phase IIa trial with heart failure patients, showing significant long-term benefits. Preclinical and clinical results with BC 007 have shown effective and lasting neutralization of fAABs after treatment. Moreover, BC 007 has proven to be safe and well-tolerated. With the ongoing Phase II trial focusing on Long COVID, Berlin Cures continues to seek additional investments and partnerships to advance this groundbreaking opportunity.

    Hashtag: #BerlinCures

    The issuer is solely responsible for the content of this announcement.

    About Berlin Cures:

    The Berlin Cures team has dedicated over two decades to the research of functional autoantibodies (fAABs) and has successfully identified a molecule capable of effectively neutralizing these. Promising preclinical results have been observed for BC 007. It was found effective in fAAB-positive healthy volunteers during the Phase I study and in heart failure patients in a Phase IIa trial, where it demonstrated long-term autoantibody neutralization after a single dose and significant improvement in cardiac function, with no spontaneous disappearance of autoantibodies in untreated patients. Its potential against Long COVID is indicated by lab data generated using sera from Long COVID patients, and four case studies. By tackling the root cause of fAAB-associated diseases with this unique biotechnology, Berlin Cures emerges as one of the pioneering entities committed to addressing this critical issue at its core.

    Since June 2023, Berlin Cures has been absolving a Phase II clinical trial with BC 007 in the indication Long COVID, an acute and escalating global health problem, to obtain meaningful and robust results on efficacy and tolerability of BC 007 with patients suffering from Long COVID.

    News from Asia

    Highbrow Unveils Its New Beauty Salon at The Adelphi

    SINGAPORE - Media OutReach Newswire - 27 June 2025 - HighBrow, one of Singapore’s most trusted names in brow, lash, and nail care, is thrilled to announce the launch of its new beauty salon at The...

    Cyberport 5 as Hong Kong's New I&T Landmark

    Driving Emerging Strategic Industries Development Heralding a New Chapter in Integration of I&T and the Community HONG KONG SAR - Media OutReach Newswire - 27 June 2025 - The Cyberport ...

    VinFast signs dealer financing cooperation agreement with BCA

    JAKARTA, INDONESIA - Media OutReach Newswire - 27 June 2025 - VinFast has officially entered into a pivotal financial partnership with PT Bank Central Asia Tbk. (BCA), one of Indonesia's leading p...

    Food Expo PRO and Hong Kong International Tea Fair Return in August with New Coffee Zone and Expanded Halal Sector

    HONG KONG SAR - Media OutReach Newswire - 27 June 2025 - Organised by the Hong Kong Trade Development Council (HKTDC), the Food Expo PRO and Hong Kong International Tea Fair will be staged concurr...

    Food Expo PRO and Hong Kong International Tea Fair: One-Stop F&B Platform Returns in August

    Spotlighting Food Science & Tech HONG KONG SAR - Media OutReach Newswire - 27 June 2025 - Organised by the Hong Kong Trade Development Council (HKTDC), the Food Expo PRO and Hong Kong Internat...

    The best CFD broker 2025': Octa receives yet another award

    KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 27 June 2025 - Octa, a globally regulated and trusted broker since 2011, was recently named 'The best CFD broker 2025' by the AllForexRating.com...

    DHL Express completes the modernization of its Air Hong Kong-operated fleet to boost Asia Pacific network capacity and fuel efficiency

    14 A330 freighters in total have been added to the regional network, retiring the previous A300-600F fleet This is part of DHL Express's ongoing investment to enhance its network ...

    Rethinking Obesity: Novo Nordisk’s Latest Initiative Urges Singaporeans to Treat, Not Blame

    “Beyond the Scale” focuses on obesity as a chronic disease — urging empathy, early intervention, and evidence-based care. SINGAPORE - Media OutReach Newswire - 27 June 2025 - Imagine a chronic dis...

    Trend Micro to Deliver AI Factory with Dell and NVIDIA for Secure Infrastructure at Scale

    Platforms to accelerate secure AI adoption for modern IT environments HONG KONG SAR - Media OutReach Newswire - 27 June 2025 - Trend Micro Incorporated (TYO: 4704; TSE: 4704), a global cybersecur...

    HKICPA renews its Mutual Recognition Agreement with ACCA

    HONG KONG SAR - Media OutReach Newswire - 27 June 2025 - The Hong Kong Institute of Certified Public Accountants (HKICPA) is delighted to announce its renewal of Mutual Recognition Agreement (MRA)...

    Demand for Home Batteries surges as Federal Rebate Kicks In

    A leading provider of energy solutions VoltX Energy has seen a 400% increase in demand for home batteries in the past three weeks as people put d...

    Why Sport Remains the Safest Bet in an Uncertain World

    When Rome was in crisis, its leaders did not retreat to the Senate. They went to the circus. To the chariot races. To the gladiators. Sport was no...

    THE FINE LINE WITHIN HILARIOUS SIGNAGE DESIGN FAILS

    It seems like design failures still occur in today’s modern branding era, despite rigorous rounds of approvals behind the scenes. One signage show...

    Deputy Announces Exclusive Global Partnership with Predelo to Bring AI to Shift-Based Businesses

    Deputy, the global people platform for shift-based businesses, has announced an exclusive partnership with Predelo, an AI Decision Agent-as-a-Serv...

    Leftover Budget? The Last-Minute EOFY Tip to Drive Business Success in FY25/26

    The countdown is on. With just days left until EOFY, now’s the time to make your remaining 2024–2025 budget work harder and smarter. After workin...

    pay.com.au appoints new CEO and Managing Director

    The former COO will lead the company’s next growth phase, with ex-CEO Edward Alder transitioning into the role of Managing Director AUSTRALIA, 25...

    Sell by LayBy